Team

The co-founders of Epoch Biotech are dedicated to developing new therapies for Alzheimer’s Disease based on the groundbreaking work identifying the underlying molecular mechanisms of resilient patients with inherited Alzheimer’s Disease.

Dean Eliott, MD

Co-Founder

Stelios Evangelos Gragoudas Professor of Ophthalmology at Harvard Medical School; Director Emeritus of the Mass. Eye and Ear Retina Service; Director of Surgical Retina Fellowship

Retina fellowship and Chief Resident at Duke University Medical Center; Ophthalmology residency at Wilmer Eye Institute/Johns Hopkins Hospital; MD (honors) from Vanderbilt University School of Medicine

Internationally recognized expert in vitreoretinal surgery

Leo A. Kim, MD, PhD

Co-Founder

Monte J. Wallace Chair in Retina; Associate Professor of Ophthalmology at Harvard Medical School

Retina fellowship and ophthalmology residency at Doheny Eye Institute / University of Southern California; MD, PhD from Yale University School of Medicine

NIH and Department of Defense funded clinician-scientist with expertise in basic science research and vitreoretinal surgery

Michael Aceti, MBA

Co-Founder and President

Over 30 years of financial and operational experience in a wide range of industries and companies including Beacon Endoscopic, Catamaran Bio, Fog Pharmaceuticals, GreenLight, Helio Vision, Innosight, Lumicell, Mercy BioAnalytics as well as in financial and commercial roles at Genzyme, GenRad, and Procter & Gamble

MBA in Finance and Strategy at The University of Chicago

Joseph Arboleda-Velasquez, MD, PhD

Co-Founder

Associate Professor of Ophthalmology at Harvard Medical School

PhD in Biological and Biomedical Sciences from Harvard, MD from University of Antioquia, Colombia

NIH and Department of Defense funded scientist with expertise in neuroscience and vision research

Discovered the APOE Christchurch variant as a resistant factor against Alzheimer’s Disease